Please assess the completion status of the following clinical trial:

Trial Title: Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Injuries in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hemodynamically stable, as determined by the trauma team~* Age 8 through 17 years~* Interpretable CT of the abdomen and pelvis that demonstrates at least one abdominal solid organ injury among the liver, spleen, pancreas, and kidneys~* Plan for observation or admission to the hospital~* Candidate for abdominal ultrasound based on body habitus~* Have a Glasgow Coma Score of 15~* Able to complete the study procedures within 48 hours of injury~Exclusion Criteria:~* Known cardiac abnormality~* Pulmonary hypertension~* Known sensitivity to sulfur hexafluoride, polyethylene glycol 4000, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Na), or palmitic acid~* Unable to roll over~* Unable to assent~* Pregnant~* Lactating~* CT images not available for transmission to central image repository

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- All Study Participants (Type: EXPERIMENTAL): All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL

Based on this trial design, predict the completion outcome and termination type (if applicable).